Approval · Notice of Compliance 15404 · 2014
DUODOPA: Notice of Compliance 15404
Issued March 12, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15404
- Date
- March 12, 2014
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfilment of commitments as per the original letter of undertaking dated february 21, 2007 and the re-issued letters of undertaking dated december 6,2010, july 8, 2010 and november 1, 2012
- Therapeutic class
- Antiparkinson agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DUODOPA | Not yet assigned | — |
Medicinal ingredients
- LEVODOPA 20 MG per ML
- CARBIDOPA MONOHYDRATE 5 MG per ML